Client News

Home/Client News
Client News 2018-08-28T11:24:45+00:00
September 5, 2017
Aradigm Announces Upcoming Data Presentations in Non-Cystic Fibrosis Bronchiectasis at the European Respiratory Society (ERS) 2017 Annual Congress
HAYWARD, Calif. -- (BUSINESS WIRE) -- Aradigm Corporation (ARDM) (the “Company”) today announced the upcoming presentation of research at the European Respiratory Society (ERS) 2017 Annual ...
September 5, 2017
Minerva Neurosciences Announces Enrollment of First Patient in Phase 2b Trial of Seltorexant (MIN-202) as Adjunctive Therapy in Patients With Major Depressive Disorder
WALTHAM, Mass., Sept. 05, 2017 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central ...
September 5, 2017
Eiger Announces FDA Orphan Drug Designation Granted for Pegylated Interferon Lambda in Hepatitis Delta Virus Infection
PALO ALTO, Calif., Sept. 5, 2017 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (EIGR), focused on the development and commercialization of targeted therapies for rare diseases, today announced ...
September 5, 2017
Lipocine to Present at the Rodman & Renshaw 19th Annual Global Investment Conference
SALT LAKE CITY, Sept. 05, 2017 (GLOBE NEWSWIRE) -- Lipocine Inc. (LPCN), a specialty pharmaceutical company, announced today that Dr. Mahesh Patel, Chairman, President and ...
September 5, 2017
Albireo to Present at 19th Annual Rodman & Renshaw Global Investment Conference
BOSTON, Sept. 05, 2017 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced ...
September 5, 2017
CytoSorbents Highlights Important Research Advances in Traumatic Brain Injury, Hemorrhagic Shock, and Severe Hyperkalemia at the Military Health System Research Symposium
MONMOUTH JUNCTION, N.J., Sept. 5, 2017 /PRNewswire/ -- CytoSorbents Corporation (CTSO), a critical care immunotherapy leader commercializing its flagship CytoSorb® blood filter to prevent or treat deadly ...
September 5, 2017
Bellerophon Announces Positive Top Line Phase 2 Data of INOpulse® for Treatment of Pulmonary Hypertension Associated with Chronic Obstructive Pulmonary Disease
WARREN, N.J., Sept. 05, 2017 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (BLPH), a clinical-stage biotherapeutics company, today announced positive top line data from a Phase 2 ...
September 5, 2017
Aptose Biosciences to Present at the 19th Annual Rodman & Renshaw Global Investment Conference
SAN DIEGO and TORONTO, Sept. 05, 2017 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (APTO) (APS.TO), a clinical-stage company developing highly differentiated therapeutics that target the ...
September 5, 2017
UroGen Pharma to Present at the Rodman & Renshaw 19th Annual Global Investment Conference
RA'ANANA, Israel, and NEW YORK, Sept. 05, 2017 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (URGN), a clinical-stage biopharmaceutical company developing treatments to address unmet needs ...
September 5, 2017
Rexahn Pharmaceuticals to Present Updated Clinical and Preclinical Data at the 2017 European Society for Medical Oncology (ESMO) Congress
ROCKVILLE, Md., Sept. 05, 2017 (GLOBE NEWSWIRE) -- Rexahn Pharmaceuticals, Inc. (NYSE MKT:RNN), a clinical stage biopharmaceutical company developing innovative, targeted therapeutics for the treatment ...
August 30, 2017
iCAD Announces Approval of Xoft® Axxent® Balloon Applicators by China Food & Drug Administration for Treatment of Early-Stage Breast Cancer
NASHUA, N.H., Aug. 30, 2017 (GLOBE NEWSWIRE) -- iCAD, Inc. (ICAD), an industry-leading provider of advanced image analysis, workflow solutions and radiation therapy for the ...
August 30, 2017
VBI Vaccines Announces FDA Acceptance of Investigational New Drug Application for Sci-B-Vac(R) Phase 3 Clinical Program
VBI Vaccines Inc. (VBIV)(VBV.TO) (VBI) today announced that the U.S. Food and Drug Administration (FDA) has accepted the company's Investigational New Drug Application (IND) for ...
August 30, 2017
Molecular Templates to Ring NASDAQ Closing Bell Friday, September 1, 2017
AUSTIN, Texas, Aug. 30, 2017 (GLOBE NEWSWIRE) -- Molecular Templates, Inc., (MTEM) a clinical stage biopharmaceutical company developing next generation immunotoxins called Engineered Toxin Bodies ...
August 30, 2017
Rexahn Pharmaceuticals Receives New U.S. Patent for Supinoxin™
ROCKVILLE, Md., Aug. 30, 2017 (GLOBE NEWSWIRE) -- Rexahn Pharmaceuticals, Inc. (NYSE MKT:RNN), a clinical stage biopharmaceutical company developing innovative, targeted therapeutics for the treatment ...
August 30, 2017
Kamada Announces Full Exercise of Underwriters’ Option to Purchase Additional Shares
REHOVOT, Israel, Aug. 30, 2017 (GLOBE NEWSWIRE) -- Kamada Ltd. (KMDA) (KMDA), a plasma-derived protein therapeutics company focused on orphan indications, today announced that the ...
August 29, 2017
Prometic Receives Rare Pediatric Disease Designation From U.S. FDA for its Plasminogen Replacement Therapy
LAVAL, QC, Aug. 29, 2017 /PRNewswire/ - Prometic Life Sciences Inc. (PLI.TO) (PFSCF) (Prometic) today announced that the U.S Food and Drug Administration (FDA) has granted ...
August 29, 2017
Arena Pharmaceuticals to Participate in Upcoming Investor Conferences
SAN DIEGO, Aug. 29, 2017 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (ARNA) today announced that members of its senior management team will participate in the following investor conferences ...
August 29, 2017
UroGen Pharma Receives FDA Fast Track Designation for MitoGel™ for the Treatment of Upper Tract Urothelial Carcinoma (UTUC)
UroGen Pharma Ltd. (URGN), a clinical-stage biopharmaceutical company developing treatments to address unmet needs in the field of urology, with a focus on uro-oncology, today ...
August 28, 2017
BioTime to Present Data at the Military Health System Research Symposium
ALAMEDA, Calif. -- (BUSINESS WIRE) -- BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on developing and commercializing products addressing degenerative diseases, today announced ...
August 28, 2017
VBL Therapeutics to Present at the Rodman & Renshaw Global Investment Conference in New York on September 10-12, 2017
TEL AVIV, Israel, Aug. 28, 2017 (GLOBE NEWSWIRE) -- VBL Therapeutics (VBLT), a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class ...
Page 95 of 117